▲
Fushine Shares Secures Japanese Invention Patent for Fusarium Protein Technology
Jiangxi Fushine Pharmaceutical Co., Ltd. announced that the company and its subsidiary Jiangxi Fushine Biotechnology Co., Ltd. have obtained an invention patent certificate issued by the Japan Patent Office. The invention is titled "Application of Fusarium oxysporum in the Production of Mycelial Protein," with Japanese patent number 7881733, a grant date of June 19, 2026, and a patent term of 20 years. The company stated that it has become the first enterprise in China to achieve thousand-ton-scale industrialization of filamentous fungal protein, and that the technology related to its proprietary strain Fusarium oxysporum has reached an internationally advanced level overall. The technology had previously been granted invention patents in China, South Korea, and the United States. This Japanese patent represents important progress in the company's international strategic layout for its microbial protein business and will provide a technical barrier for the entry of its Weiran brand protein products into the Japanese market. The patent has already been applied to existing production lines and is not expected to have a significant impact on near-term performance, but it holds positive strategic significance for long-term business development.
▲
BSF shares jump 56% on US joint venture for lab-grown leather
BSF Enterprise shares soared 56.5% to 1.33 pence after the tissue engineering company agreed outline terms for a joint venture to sell its lab-grown leather into the American luxury market. The London-listed group signed non-binding heads of terms with US brand operator IMPOSTER to form a 50/50 venture, with BSF contributing technology licensing and material supply while IMPOSTER provides operational funding of between 500,000 and 1 million dollars drawn from a planned 3.5 million dollar growth capital raise. Full commercial exclusivity for the venture only activates once that funding is received. The venture will focus on small luxury items such as bag charms, keyrings, desk accessories, equestrian goods, and a limited run of bespoke handbags and wallets, while BSF retains all intellectual property and commercial rights in higher-volume categories including mainline footwear, apparel, automotive interiors, and mass-market handbags. BSF is targeting three revenue streams: a gross margin of 25 to 35 percent on raw material transfers, a royalty of 3 to 7 percent on net sales, and half of any venture profits.
Angel Yeast Subsidiary Plans to Invest 370 Million Yuan in New Synthetic Biology Pilot Verification Base
Angel Yeast's wholly-owned subsidiary, Angel Enzyme Preparation Yichang Company, plans to invest 370 million yuan to build a new synthetic biology pilot verification base project. The project has been approved by the board of directors and still needs to be submitted to the shareholders' meeting for review and relevant authorities for approval. The project will construct an extraction workshop and a fermentation workshop on reserved land of the enzyme preparation company, with a construction period of 16 months, expected to start in March 2027, and funds will be self-raised by the company. According to calculations, the project is expected to have an investment return rate of 9.79 percent, offering good investment returns and risk resistance. Angel Yeast stated that the project aligns with the company's medium- and long-term development strategy for synthetic biology, will build an integrated pilot platform, accelerate the industrialization of new industrial enzyme preparations, novel microbial proteins, and other products, and enhance the company's core competitiveness in the field of biomanufacturing.
